Centessa Pharmaceuticals plc
CNTA
$39.76
$0.060.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 42.07% | 14.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.50% | 27.30% | |||
| Operating Income | -16.50% | -27.30% | |||
| Income Before Tax | -17.55% | -21.85% | |||
| Income Tax Expenses | 262.84% | -414.46% | |||
| Earnings from Continuing Operations | -19.77% | -20.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.77% | -20.54% | |||
| EBIT | -16.50% | -27.30% | |||
| EBITDA | -16.29% | -27.71% | |||
| EPS Basic | -10.75% | -13.91% | |||
| Normalized Basic EPS | -8.72% | -15.14% | |||
| EPS Diluted | -10.75% | -13.91% | |||
| Normalized Diluted EPS | -8.72% | -15.14% | |||
| Average Basic Shares Outstanding | 8.15% | 5.83% | |||
| Average Diluted Shares Outstanding | 8.15% | 5.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||